The BDB Pitmans corporate team has acted for client, SourceBio International Plc (‘SourceBio’), on its successful admission to trading on the AIM market of the London Stock Exchange with a market capitalisation of just over £120 million. The firm also acted on a placing as part of the IPO to raise £35 million for SourceBio from institutional investors, which attracted strong support from high quality institutional investors and was significantly over-subscribed.
SourceBio is a leading international provider of integrated state-of-the-art laboratory services and products for the healthcare, clinical, life science research and biopharma industries, with a focus on improving patient diagnosis management and care. SourceBio’s core business areas include healthcare diagnostics, genomics, stability storage and infectious disease testing.
‘We are delighted to have assisted SourceBio International Plc on its successful IPO onto the AIM market of the London Stock Exchange and look forward to the opportunity of working with its experienced team in the future.’
